37 articles for R Zahler
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
14
Synthesis of potent and highly selective inhibitors of human tryptase.
The Bristol-Myers Squibb Pharmaceutical Research Institute
19
Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
The Bristol-Myers Squibb Pharmaceutical Research Institute
19
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.
Bristol Myers Squibb
44
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARa/¿ agonists.
Bristol Myers Squibb
27
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).
Bristol Myers Squibb
20
Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.
Bristol Myers Squibb
22
Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.
Bristol Myers Squibb
17
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Bristol Myers Squibb
45
Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
The Bristol-Myers Squibb Pharmaceutical Research Institute
33
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Bristol Myers Squibb
32
Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Bristol Myers Squibb
33
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
Bristol Myers Squibb
25
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
Bristol Myers Squibb
14
Aminodiol HIV protease inhibitors. 2. 1,1-Dimethyl-2-hydroxyethyl carbamate derivatives with enhanced potency
TBA
22
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Bristol Myers Squibb
19
Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Bristol Myers Squibb
25
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators.
Pharmaceutical Research Institute
24
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Pharmaceutical Research Institute
27
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.
Bristol Myers Squibb
26
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1
Bristol Myers Squibb
15
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.
Syros Pharmaceuticals
23
Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.
The Bristol-Myers Squibb Pharmaceutical Research Institute
25
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Bristol Myers Squibb
160
ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS
Merck Sharp & Dohme
86
Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein
The Governing Council of The University of Toronto
37
Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
Shionogi
33
Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof
Universite Paris Descartes
24
3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors
Nerviano Medical Sciences
9
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.
Uppsala University
4
Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.
Lawrence Berkeley National Laboratory